Data is very encouraging. Presently this battle is essentially a race between the current vaccines (which data indicates are very effective against current strains) and eventual variants that will make the current vaccines less effective (or in the worst case ineffective). The mutations aren’t really a question of if just when. Vaccine data on some new strains is concerning and potentially an early warning of things…
The mutations are far more likely if you give Regeneron to cancer patients and other immuno-compromised people. What an ethical problem... give a therapy knowing that the therapy will kill off the virus identified by the therapy but with a higher chance that mutations in the patient become free to propagate, or don't administer the immuno-therapy to the most vulnerable people in an attempt to stem early mutation? Since only the rich are getting Regeneron, it really is a case of class warfare.
